Acceleron Pharma

Traded on the St. Petersburg Stock Exchange
Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company focus on developing medicine, which play fundamental roles in the growth and repair of cells and tissues.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Acceleron Pharma balance sheet

Report period2016 2017 2018 2019 2020 Q3 21
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Acceleron Pharma cash flows

Report period2016 2017 2018 2019 2020 Q3 21 TTM
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Acceleron Pharma multipliers

Report period2016 2017 2018 2019 2020 Q3 21 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Acceleron Pharma profitability

Report period2016 2017 2018 2019 2020 Q3 21 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Acceleron Pharma assets
Acceleron Pharma cash flows
Acceleron Pharma news
22.11.2021
Merck & Co completed its acquisition of Acceleron Pharma for $11.5 billion, or $180 per share.
Source: {source} pictogram merck.com
09.11.2021
German and Austrian antitrust authorities have approved a deal for Merck & Co. to acquire Acceleron Pharma for $11.5 billion, or $180 a share. The company specializes in the development of protein therapies for cancer treatment, as well as the search and development of drugs for rare hematological and lung diseases. The deal is scheduled to close in Q4 2021.
Source: {source} pictogram merck.com
05.11.2021
Acceleron Pharma's GAAP loss for 9M 2021 was $197.457 million, up 81.8% from $108.635 million in the previous year. Revenue increased 30.4% to $86.897 million from $66.656 million a year earlier.
30.09.2021
Merck & Co. acquires Acceleron Pharma for $11.5 million, or $180 per share. The deal is scheduled to close in Q4 2021.
Source: {source} pictogram merck.com
General information
Company nameAcceleron Pharma
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address128 SIDNEY STREET CAMBRIDGE MA 02139 617-649-9200
Mailing address128 SIDNEY STREET CAMBRIDGE MA 02139
Websitewww.acceleronpharma.com
Information disclosurewww.sec.gov